Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Aringer

Showing results (31-40 of 216) with videos related to

Pageof 22
Sort By:
Deutsche Medizinische Wochenschrift (1946)|May 1, 2021
[Polyarthritis - From symptoms to diagnosis]Kristin Wiefel, Martin Aringer
Annals of the Rheumatic Diseases|December 15, 2020
Response to: 'Correspondence on 'Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities'' by Rönnelid <i>et al</i>Sindhu R Johnson, Martin Aringer
Arthritis Care & Research|July 24, 2018
How Should We Consider Lupus Without Antinuclear Antibodies?David I Daikh, Martin Aringer
Autoimmunity Reviews|May 31, 2011
Therapeutic blockade of TNF in patients with SLE-promising or crazy?Martin Aringer, Josef S Smolen
Arthritis & Rheumatology (Hoboken, N.J.)|May 13, 2025
The Dynamics of ANA Production in SLE: New Insights for New TherapiesMartin Aringer, David S Pisetsky
The Journal of Rheumatology|August 2, 2008
A bridge between interferon-alpha and tumor necrosis factor in lupusMartin Aringer, Mary K Crow
Expert Opinion on Drug Safety|July 11, 2008
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Deutsche Medizinische Wochenschrift (1946)|December 1, 2016
[Lupus erythematosus - Update 2016]Martin Aringer, Reinhard Edmund Voll
Best Practice & Research. Clinical Rheumatology|September 10, 2005
New treatments for SLE: cell-depleting and anti-cytokine therapiesJennifer H Anolik, Martin Aringer
Arthritis Research & Therapy|January 30, 2008
The role of tumor necrosis factor-alpha in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Pageof 22

Showing results (31-40 of 216) with videos related to

Sort By:
Pageof 22
Deutsche Medizinische Wochenschrift (1946)|May 1, 2021
[Polyarthritis - From symptoms to diagnosis]Kristin Wiefel, Martin Aringer
Annals of the Rheumatic Diseases|December 15, 2020
Response to: 'Correspondence on 'Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities'' by Rönnelid <i>et al</i>Sindhu R Johnson, Martin Aringer
Arthritis Care & Research|July 24, 2018
How Should We Consider Lupus Without Antinuclear Antibodies?David I Daikh, Martin Aringer
Autoimmunity Reviews|May 31, 2011
Therapeutic blockade of TNF in patients with SLE-promising or crazy?Martin Aringer, Josef S Smolen
Arthritis & Rheumatology (Hoboken, N.J.)|May 13, 2025
The Dynamics of ANA Production in SLE: New Insights for New TherapiesMartin Aringer, David S Pisetsky
The Journal of Rheumatology|August 2, 2008
A bridge between interferon-alpha and tumor necrosis factor in lupusMartin Aringer, Mary K Crow
Expert Opinion on Drug Safety|July 11, 2008
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Deutsche Medizinische Wochenschrift (1946)|December 1, 2016
[Lupus erythematosus - Update 2016]Martin Aringer, Reinhard Edmund Voll
Best Practice & Research. Clinical Rheumatology|September 10, 2005
New treatments for SLE: cell-depleting and anti-cytokine therapiesJennifer H Anolik, Martin Aringer
Arthritis Research & Therapy|January 30, 2008
The role of tumor necrosis factor-alpha in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Pageof 22